Trials Sponsors Conditions Drugs Pricing

Conditions

Antimicrobial Susceptibility Testing Triple Therapy

Keywords

Helicobacter Pylori InfectionAntimicrobial susceptibility testing (AST)Triple Therapy

Outcome Measures

Primary Outcomes (1)

Eradication rate of AST guided triple therapy
3 months

Secondary Outcomes (3)

the rate of improving dyspepsia symptoms after H. pylori eradication
3 months
the rate of adverse events happening
3 months
the rate of good compliance (take pills more than 90%)
3 months

Study Arms (5)

clarithromycin susceptible

EXPERIMENTAL

Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI).

Drug: amoxicillinDrug: clarithromycinDrug: Ilaprazole

metronidazole susceptible

EXPERIMENTAL

Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.

Drug: amoxicillinDrug: tinidazoleDrug: Ilaprazole

Interventions

amoxicillinDrug

amoxicillin 1000 mg bid. for 14 days

clarithromycin susceptiblefurazolidone susceptiblelevofloxacin susceptiblemetronidazole susceptibletetracycline susceptible

clarithromycinDrug

Eligibility Criteria

Age18 Years - 70 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Consecutive patients who are 18-70 years old with persistent H. pylori infection after first or second line treatment attempts.

You may not qualify if:

Sponsors & Collaborators

Yanqing Li
Otherlead

MeSH Terms

Interventions

AmoxicillinClarithromycinTinidazoleLevofloxacinFurazolidoneTetracyclineilaprazole

Intervention Hierarchy (Ancestors)

AmpicillinPenicillin GPenicillinsbeta-LactamsLactamsAmidesOrganic ChemicalsSulfur Compounds

Study Officials

Li Yanqing, MD, PhD
Qilu Hospital of Shandong University
PRINCIPAL INVESTIGATOR

Central Study Contacts

Li Yanqing, MD, PhD

CONTACT

86-531-82169236 liyanqing@sdu.edu.cn

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Vice president of Qilu Hospital

Study Record Dates

First Submitted

April 23, 2017

First Posted

May 3, 2017

Study Start

May 30, 2017

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

June 30, 2017

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (5)

clarithromycin susceptible

metronidazole susceptible

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

levofloxacin susceptible

furazolidone susceptible

tetracycline susceptible

Data Sharing

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (5)

clarithromycin susceptible

metronidazole susceptible

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

levofloxacin susceptible

furazolidone susceptible

tetracycline susceptible

Data Sharing

Source record